Harmony Biosciences Holdings (HRMY) EBITDA Margin (2020 - 2026)
Harmony Biosciences Holdings recorded quarterly EBITDA Margin of 14.73% in Q1 2026, up 59.78% quarter-over-quarter from 9.22% in Q4 2025, and down 1003.0% year-over-year from 1.63% in Q1 2025.
Harmony Biosciences Holdings' EBITDA Margin history runs 7 years deep, the most recent figure standing at 14.73% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 1003.0% year-over-year to 14.73%; the TTM figure through Mar 2026 stood at 16.12% (down 444.0% YoY), while the FY2025 annual figure was 18.3%, down 206.0% from the prior year.
- EBITDA Margin came in at 14.73% for Q1 2026 at Harmony Biosciences Holdings, up from 9.22% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 74.91% in Q3 2022 to a low of 6.67% in Q2 2024.
- A 5-year average of 24.75% and a median of 24.37% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin surged 8682 bps in 2022 and tumbled 5090 bps in 2023, its largest moves.
- Harmony Biosciences Holdings' EBITDA Margin stood at 37.83% in 2022, then plunged by 57 bps to 16.11% in 2023, then surged by 51 bps to 24.37% in 2024, then slumped by 62 bps to 9.22% in 2025, then surged by 60 bps to 14.73% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 14.73%, 9.22%, and 21.29% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn | 14.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.73% |
| Dec 31, 2025 | 9.22% |
| Sep 30, 2025 | 21.29% |
| Jun 30, 2025 | 19.84% |
| Mar 31, 2025 | 24.76% |
| Dec 31, 2024 | 24.37% |
| Sep 30, 2024 | 25.17% |
| Jun 30, 2024 | 6.67% |
| Mar 31, 2024 | 24.68% |
| Dec 31, 2023 | 16.11% |
| Sep 30, 2023 | 24.00% |
| Jun 30, 2023 | 25.19% |
| Mar 31, 2023 | 24.85% |
| Dec 31, 2022 | 37.83% |
| Sep 30, 2022 | 74.91% |
| Jun 30, 2022 | 21.96% |
| Mar 31, 2022 | 25.18% |
| Dec 31, 2021 | 24.90% |
| Sep 30, 2021 | -11.92% |
| Jun 30, 2021 | 19.12% |
| Mar 31, 2021 | 24.35% |
| Dec 31, 2020 | 13.78% |
| Sep 30, 2020 | 22.76% |
| Jun 30, 2020 | 19.23% |
| Mar 31, 2020 | -48.43% |